Nénan Soazig, Boichot Elisabeth, Lagente Vincent, Bertrand Claude P
Pfizer Global R&D, Fresnes Laboratories, Fresnes, France.
Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1:167-72. doi: 10.1590/s0074-02762005000900028. Epub 2005 Jun 14.
As many metalloproteinases (MMPs), macrophage elastase (MMP-12) is able to degrade extracellular matrix components such as elastin and is involved in tissue remodeling processes. Studies using animal models of acute and chronic pulmonary inflammatory diseases, such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), have given evidences that MMP-12 is an important mediator of the pathogenesis of these diseases. However, as very few data regarding the direct involvement of MMP-12 in inflammatory process in the airways were available, we have instilled a recombinant form of human MMP-12 (rhMMP-12) in mouse airways. Hence, we have demonstrated that this instillation induced a severe inflammatory cell recruitment characterized by an early accumulation of neutrophils correlated with an increase in proinflammatory cytokines and in gelatinases and then by a relatively stable recruitment of macrophages in the lungs over a period of ten days. Another recent study suggests that resident alveolar macrophages and recruited neutrophils are not involved in the delayed macrophage recruitment. However, epithelial cells could be one of the main targets of rhMMP-12 in our model. We have also reported that a corticoid, dexamethasone, phosphodiesterase 4 inhibitor, rolipram and a non-selective MMP inhibitor, marimastat could reverse some of these inflammatory events. These data indicate that our rhMMP-12 model could mimic some of the inflammatory features observed in COPD patients and could be used for the pharmacological evaluation of new anti-inflammatory treatment. In this review, data demonstrating the involvement of MMP-12 in the pathogenesis of pulmonary fibrosis and COPD as well as our data showing a pro-inflammatory role for MMP-12 in mouse airways will be summarized.
与许多金属蛋白酶(MMPs)一样,巨噬细胞弹性蛋白酶(MMP - 12)能够降解细胞外基质成分,如弹性蛋白,并参与组织重塑过程。使用急性和慢性肺部炎症性疾病动物模型(如肺纤维化和慢性阻塞性肺疾病(COPD))的研究表明,MMP - 12是这些疾病发病机制的重要介质。然而,由于关于MMP - 12直接参与气道炎症过程的数据非常少,我们已将重组形式的人MMP - 12(rhMMP - 12)注入小鼠气道。因此,我们已证明这种注入会诱导严重的炎症细胞募集,其特征是中性粒细胞早期积聚,与促炎细胞因子和明胶酶增加相关,随后在十天内肺部巨噬细胞募集相对稳定。另一项近期研究表明,常驻肺泡巨噬细胞和募集的中性粒细胞不参与延迟的巨噬细胞募集。然而,上皮细胞可能是我们模型中rhMMP - 12的主要靶标之一。我们还报告说,一种皮质类固醇、地塞米松、磷酸二酯酶4抑制剂咯利普兰和一种非选择性MMP抑制剂马立马司他可以逆转其中一些炎症事件。这些数据表明,我们的rhMMP - 12模型可以模拟COPD患者中观察到的一些炎症特征,并可用于新抗炎治疗的药理学评估。在这篇综述中,将总结证明MMP - 12参与肺纤维化和COPD发病机制的数据以及我们显示MMP - 12在小鼠气道中具有促炎作用的数据。